Last reviewed · How we verify

NCT06676254

Role of HbA1c in Predicting Adverse Pregnancy Outcomes

Recruiting now Last updated 6 November 2024
What this trial tests

trial in Gestational Diabetes in 195 participants. Currently enrolling.

Timeline
27 June 2024
Primary endpoint
26 June 2026
26 June 2026

Quick facts

Lead sponsorNational University of Malaysia
StatusRecruiting now
Study typeOBSERVATIONAL
Enrollment195
Start date27 June 2024
Primary completion26 June 2026
Estimated completion26 June 2026
Sites1 location across Malaysia

Conditions studied

Sponsor

National University of Malaysia

Who can join

Eligibility, female only, with Gestational Diabetes. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This study aims to determine the reference value of HbA1c that can be used to predict adverse pregnancy outcomes. These adverse outcomes include LGA fetus, shoulder dystocia, caesarean section, pre-term birth, pre-eclampsia and fetal neonatal hypoglycaemia.

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other recruiting trials for Gestational Diabetes

Currently open trials in the same condition.

Other National University of Malaysia trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06676254.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing